Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics
A frequent complication of Clostridium difficile infection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C. difficile. Consecutive pa...
Gespeichert in:
Veröffentlicht in: | Clinical microbiology and infection 2018-01, Vol.24 (1), p.85.e1-85.e4 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 85.e4 |
---|---|
container_issue | 1 |
container_start_page | 85.e1 |
container_title | Clinical microbiology and infection |
container_volume | 24 |
creator | van Beurden, Y.H. Nezami, S. Mulder, C.J.J. Vandenbroucke-Grauls, C.M.J.E. |
description | A frequent complication of Clostridium difficile infection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C. difficile.
Consecutive patients diagnosed with CDI between May 2013 and March 2014 were included (outbreak strain, and non-outbreak strains). Patients who developed recurrent CDI within 30 days after completion of CDI treatment, were compared with patients without a recurrence. Medical charts were reviewed for demographic and clinical characteristics. General practitioners were contacted to complete data about the occurrence of recurrent CDI, and the use of medication after hospital discharge.
In total, 135 patients were at risk for the development of recurrent CDI; 74 patients were infected by ribotype 027, and 61 patients by other ribotypes. Thirty-nine patients (29%) developed recurrent CDI within 30 days after completion of CDI treatment. In multivariable analysis, age ≥70 years (HR 3.05, 95% CI 1.54–6.03), and a duration of CDI treatment ≥11 days (HR 1.92, 95% CI 1.00–3.69) were clearly associated with recurrence; infection with ribotype 027 showed a HR of 1.72 (95% CI 0.88–3.33).
During this outbreak of C. difficile in a tertiary care centre, age and a prolonged duration of CDI therapy (which is most likely a marker of underlying disease severity) were the main risk factors for recurrent CDI. This points to host factors as more important predictors for recurrent CDI than strain type or antibiotic use. |
doi_str_mv | 10.1016/j.cmi.2017.07.025 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1926979962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1198743X17304093</els_id><sourcerecordid>1926979962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-848a20d2f1b7045d88c2d8adb3ca7f9c0b72b567f748bde5898f5ee3c645c9b33</originalsourceid><addsrcrecordid>eNp9kE1rFTEUhgdRbK3-ADeSpZu5TTIfSXAlF7WFghsFdyEfJ3ouM8mYZISCP96UW10Kh-QQnveFPF33mtEDo2y-Ph3cigdOmTjQNnx60l2ycVY9nRV72namZC_G4dtF96KUE6WUD8P4vLvgUkg-j-Ky-32TSiXBuJpyISYDWVM7cN1SriZWgpFsGTy6ivE7yeD2nKG9H5cWzOhxX4nHENDh0nIxQCNTJPWHiSSjTfV-A2KiJ3sBkkJbK1pMFV152T0LZinw6vG-6r5-_PDleNPfff50e3x_17tBzbWXozSceh6YFXScvJSOe2m8HZwRQTlqBbfTLIIYpfUwSSXDBDC4eZycssNw1b099245_dyhVL1icbAsJkLai2aKz0ooNfOGsjPqciolQ9BbxtXke82ofpCuT7pJ1w_SNW3Dp5Z581i_2xX8v8Rfyw14dwagffIXQtbFIUTXtDahVfuE_6n_A7IClYo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1926979962</pqid></control><display><type>article</type><title>Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>van Beurden, Y.H. ; Nezami, S. ; Mulder, C.J.J. ; Vandenbroucke-Grauls, C.M.J.E.</creator><creatorcontrib>van Beurden, Y.H. ; Nezami, S. ; Mulder, C.J.J. ; Vandenbroucke-Grauls, C.M.J.E.</creatorcontrib><description>A frequent complication of Clostridium difficile infection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C. difficile.
Consecutive patients diagnosed with CDI between May 2013 and March 2014 were included (outbreak strain, and non-outbreak strains). Patients who developed recurrent CDI within 30 days after completion of CDI treatment, were compared with patients without a recurrence. Medical charts were reviewed for demographic and clinical characteristics. General practitioners were contacted to complete data about the occurrence of recurrent CDI, and the use of medication after hospital discharge.
In total, 135 patients were at risk for the development of recurrent CDI; 74 patients were infected by ribotype 027, and 61 patients by other ribotypes. Thirty-nine patients (29%) developed recurrent CDI within 30 days after completion of CDI treatment. In multivariable analysis, age ≥70 years (HR 3.05, 95% CI 1.54–6.03), and a duration of CDI treatment ≥11 days (HR 1.92, 95% CI 1.00–3.69) were clearly associated with recurrence; infection with ribotype 027 showed a HR of 1.72 (95% CI 0.88–3.33).
During this outbreak of C. difficile in a tertiary care centre, age and a prolonged duration of CDI therapy (which is most likely a marker of underlying disease severity) were the main risk factors for recurrent CDI. This points to host factors as more important predictors for recurrent CDI than strain type or antibiotic use.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1016/j.cmi.2017.07.025</identifier><identifier>PMID: 28782647</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aged ; Aged, 80 and over ; Anti-Bacterial Agents - therapeutic use ; Clostridium difficile - classification ; Clostridium difficile - drug effects ; Clostridium difficile - isolation & purification ; Clostridium Infections - diagnosis ; Clostridium Infections - drug therapy ; Clostridium Infections - epidemiology ; Cross Infection - epidemiology ; Cross Infection - microbiology ; Disease Outbreaks ; Female ; Host factors ; Humans ; Male ; Netherlands - epidemiology ; Outbreak ; Recurrence ; Recurrent Clostridium difficile infection (CDI) ; Ribotype 027 ; Ribotyping ; Risk Factors ; Tertiary Care Centers</subject><ispartof>Clinical microbiology and infection, 2018-01, Vol.24 (1), p.85.e1-85.e4</ispartof><rights>2017 European Society of Clinical Microbiology and Infectious Diseases</rights><rights>Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-848a20d2f1b7045d88c2d8adb3ca7f9c0b72b567f748bde5898f5ee3c645c9b33</citedby><cites>FETCH-LOGICAL-c396t-848a20d2f1b7045d88c2d8adb3ca7f9c0b72b567f748bde5898f5ee3c645c9b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28782647$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Beurden, Y.H.</creatorcontrib><creatorcontrib>Nezami, S.</creatorcontrib><creatorcontrib>Mulder, C.J.J.</creatorcontrib><creatorcontrib>Vandenbroucke-Grauls, C.M.J.E.</creatorcontrib><title>Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics</title><title>Clinical microbiology and infection</title><addtitle>Clin Microbiol Infect</addtitle><description>A frequent complication of Clostridium difficile infection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C. difficile.
Consecutive patients diagnosed with CDI between May 2013 and March 2014 were included (outbreak strain, and non-outbreak strains). Patients who developed recurrent CDI within 30 days after completion of CDI treatment, were compared with patients without a recurrence. Medical charts were reviewed for demographic and clinical characteristics. General practitioners were contacted to complete data about the occurrence of recurrent CDI, and the use of medication after hospital discharge.
In total, 135 patients were at risk for the development of recurrent CDI; 74 patients were infected by ribotype 027, and 61 patients by other ribotypes. Thirty-nine patients (29%) developed recurrent CDI within 30 days after completion of CDI treatment. In multivariable analysis, age ≥70 years (HR 3.05, 95% CI 1.54–6.03), and a duration of CDI treatment ≥11 days (HR 1.92, 95% CI 1.00–3.69) were clearly associated with recurrence; infection with ribotype 027 showed a HR of 1.72 (95% CI 0.88–3.33).
During this outbreak of C. difficile in a tertiary care centre, age and a prolonged duration of CDI therapy (which is most likely a marker of underlying disease severity) were the main risk factors for recurrent CDI. This points to host factors as more important predictors for recurrent CDI than strain type or antibiotic use.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Clostridium difficile - classification</subject><subject>Clostridium difficile - drug effects</subject><subject>Clostridium difficile - isolation & purification</subject><subject>Clostridium Infections - diagnosis</subject><subject>Clostridium Infections - drug therapy</subject><subject>Clostridium Infections - epidemiology</subject><subject>Cross Infection - epidemiology</subject><subject>Cross Infection - microbiology</subject><subject>Disease Outbreaks</subject><subject>Female</subject><subject>Host factors</subject><subject>Humans</subject><subject>Male</subject><subject>Netherlands - epidemiology</subject><subject>Outbreak</subject><subject>Recurrence</subject><subject>Recurrent Clostridium difficile infection (CDI)</subject><subject>Ribotype 027</subject><subject>Ribotyping</subject><subject>Risk Factors</subject><subject>Tertiary Care Centers</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rFTEUhgdRbK3-ADeSpZu5TTIfSXAlF7WFghsFdyEfJ3ouM8mYZISCP96UW10Kh-QQnveFPF33mtEDo2y-Ph3cigdOmTjQNnx60l2ycVY9nRV72namZC_G4dtF96KUE6WUD8P4vLvgUkg-j-Ky-32TSiXBuJpyISYDWVM7cN1SriZWgpFsGTy6ivE7yeD2nKG9H5cWzOhxX4nHENDh0nIxQCNTJPWHiSSjTfV-A2KiJ3sBkkJbK1pMFV152T0LZinw6vG-6r5-_PDleNPfff50e3x_17tBzbWXozSceh6YFXScvJSOe2m8HZwRQTlqBbfTLIIYpfUwSSXDBDC4eZycssNw1b099245_dyhVL1icbAsJkLai2aKz0ooNfOGsjPqciolQ9BbxtXke82ofpCuT7pJ1w_SNW3Dp5Z581i_2xX8v8Rfyw14dwagffIXQtbFIUTXtDahVfuE_6n_A7IClYo</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>van Beurden, Y.H.</creator><creator>Nezami, S.</creator><creator>Mulder, C.J.J.</creator><creator>Vandenbroucke-Grauls, C.M.J.E.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201801</creationdate><title>Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics</title><author>van Beurden, Y.H. ; Nezami, S. ; Mulder, C.J.J. ; Vandenbroucke-Grauls, C.M.J.E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-848a20d2f1b7045d88c2d8adb3ca7f9c0b72b567f748bde5898f5ee3c645c9b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Clostridium difficile - classification</topic><topic>Clostridium difficile - drug effects</topic><topic>Clostridium difficile - isolation & purification</topic><topic>Clostridium Infections - diagnosis</topic><topic>Clostridium Infections - drug therapy</topic><topic>Clostridium Infections - epidemiology</topic><topic>Cross Infection - epidemiology</topic><topic>Cross Infection - microbiology</topic><topic>Disease Outbreaks</topic><topic>Female</topic><topic>Host factors</topic><topic>Humans</topic><topic>Male</topic><topic>Netherlands - epidemiology</topic><topic>Outbreak</topic><topic>Recurrence</topic><topic>Recurrent Clostridium difficile infection (CDI)</topic><topic>Ribotype 027</topic><topic>Ribotyping</topic><topic>Risk Factors</topic><topic>Tertiary Care Centers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Beurden, Y.H.</creatorcontrib><creatorcontrib>Nezami, S.</creatorcontrib><creatorcontrib>Mulder, C.J.J.</creatorcontrib><creatorcontrib>Vandenbroucke-Grauls, C.M.J.E.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Beurden, Y.H.</au><au>Nezami, S.</au><au>Mulder, C.J.J.</au><au>Vandenbroucke-Grauls, C.M.J.E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics</atitle><jtitle>Clinical microbiology and infection</jtitle><addtitle>Clin Microbiol Infect</addtitle><date>2018-01</date><risdate>2018</risdate><volume>24</volume><issue>1</issue><spage>85.e1</spage><epage>85.e4</epage><pages>85.e1-85.e4</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>A frequent complication of Clostridium difficile infection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C. difficile.
Consecutive patients diagnosed with CDI between May 2013 and March 2014 were included (outbreak strain, and non-outbreak strains). Patients who developed recurrent CDI within 30 days after completion of CDI treatment, were compared with patients without a recurrence. Medical charts were reviewed for demographic and clinical characteristics. General practitioners were contacted to complete data about the occurrence of recurrent CDI, and the use of medication after hospital discharge.
In total, 135 patients were at risk for the development of recurrent CDI; 74 patients were infected by ribotype 027, and 61 patients by other ribotypes. Thirty-nine patients (29%) developed recurrent CDI within 30 days after completion of CDI treatment. In multivariable analysis, age ≥70 years (HR 3.05, 95% CI 1.54–6.03), and a duration of CDI treatment ≥11 days (HR 1.92, 95% CI 1.00–3.69) were clearly associated with recurrence; infection with ribotype 027 showed a HR of 1.72 (95% CI 0.88–3.33).
During this outbreak of C. difficile in a tertiary care centre, age and a prolonged duration of CDI therapy (which is most likely a marker of underlying disease severity) were the main risk factors for recurrent CDI. This points to host factors as more important predictors for recurrent CDI than strain type or antibiotic use.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28782647</pmid><doi>10.1016/j.cmi.2017.07.025</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1198-743X |
ispartof | Clinical microbiology and infection, 2018-01, Vol.24 (1), p.85.e1-85.e4 |
issn | 1198-743X 1469-0691 |
language | eng |
recordid | cdi_proquest_miscellaneous_1926979962 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Aged Aged, 80 and over Anti-Bacterial Agents - therapeutic use Clostridium difficile - classification Clostridium difficile - drug effects Clostridium difficile - isolation & purification Clostridium Infections - diagnosis Clostridium Infections - drug therapy Clostridium Infections - epidemiology Cross Infection - epidemiology Cross Infection - microbiology Disease Outbreaks Female Host factors Humans Male Netherlands - epidemiology Outbreak Recurrence Recurrent Clostridium difficile infection (CDI) Ribotype 027 Ribotyping Risk Factors Tertiary Care Centers |
title | Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T01%3A58%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Host%20factors%20are%20more%20important%20in%20predicting%20recurrent%20Clostridium%20difficile%20infection%20than%20ribotype%20and%20use%20of%20antibiotics&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=van%20Beurden,%20Y.H.&rft.date=2018-01&rft.volume=24&rft.issue=1&rft.spage=85.e1&rft.epage=85.e4&rft.pages=85.e1-85.e4&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1016/j.cmi.2017.07.025&rft_dat=%3Cproquest_cross%3E1926979962%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1926979962&rft_id=info:pmid/28782647&rft_els_id=S1198743X17304093&rfr_iscdi=true |